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Abstract 
Background: The presence of beta-2microglobulin (β2M) in biological fluids due to lack of binding to the 
membrane, increases at the time of cell turnover such as cancer and chronic infectious. In recent years, study on the 
standardization of saliva for clinical diagnosis is increased. The objective of this study was to determine β2M levels 
and the relationship between salivary and serum β2M in Prostate cancer (PCa) and Benign prostatic hyperplasia 
(BPH) patients.  
Materials and Methods: In a case-control study, forty Subjects including 20 PCa and 20 BPH were enrolled. The 
concentration of β2M was measured by an enzyme-linked immunosorbent assay. The comparison between β2M 
levels in the PCa and BPH groups as well as the correlation between salivary and serum β2M were  tested using 
Mann-Whitney U test and spearman correlation coefficient, respectively.  
Results: Statistically significant difference was observed between salivary and serum β2M in the PCa and BPH 
groups (P<0.05). Spearman correlation analysis showed that salivary β2M is correlated positive and significantly 
with serum β2M in the PCa (r = 0.747, P < 0.05) and BPH (r = 0.513, P < 0.05) groups.  
Conclusion: β2M can be a suitable biomarker for the diagnosis of prostate diseases, as well as salivary β2M can be 
used as an alternative approach to serum β2M for monitoring and diagnosis of prostate diseases. 
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The most common prostate diseases are 
prostate cancer (PCa) and benign prostatic 
hyperplasia (BPH). PCa is the second leading cause 
of cancer related death among men, while BPH is 
non-cancerous enlargement of the prostate gland that 
often occurs with aging (1, 2). Early detection is the 
important way for cancer treatment. such that, 
delayed diagnosis contributes to cancer progression 
and lead to loss of the initiative to treat it (3). The 
incidence of prostate cancer has decreased due to early 
detection and identify factors specific diagnosis (3, 4). 
Despite the advanced diagnostic methods, such as 
magnetic resonance imaging (MRI), computed 
tomography (CT) and  biopsy, these methods cause 
suffering and impose heavy costs on patients (5). As a 
result, studies have great interest in tumor markers due 
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to they are simple, low cost, and relatively sensitive 
screening tool for detecting malignancies. These 
biomarker also   increased in the presence of cancer 
and found in blood, urine and body tissues, and are 
used in cancer care including diagnosis, screening, 
monitoring, staging and prognosis (6). Beta-2 
microglobulin (β2M) constitutes a (11.8 kDa) light 
chain of the major histocompatibility complex class I 
(MHCI). β2M is produced in all nucleated cells. 
Studies have shown increased β2M in tissue/serum of 
breast, lung, gastrointestinal, gastrointestinal and 
prostate cancer cells (7). Based on studies, saliva can 
show the tumor markers such as PSA in prostate 
cancer (8), CA15-3 in ovarian cancer (9), CA125 in 
ovarian cancer(10), etc. Therefore, the use of saliva 
as a biological fluid could be beneficial due to non-
invasive, inexpensive, no need for special equipment 
and special techniques and repeated sampling 
without suffering of patients  
     The aim of this study was to assess the 
salivary and serum β2M levels and the relationship 
between salivary and serum β2M in patients with 
prostate cancer and benign prostatic hyperplasia. 
Methods 
Study design. This study was designed as a  
case–control study in Arak University of Medical 
Sciences, Arak, IR Iran and governmental referral 
hospital Ayatollah Khan Sari in Arak, IR Iran for 1 
year’s duration on 40 men  aged between 50 to 55 
years. An ethical clearance was obtained from the 
ethical committee of the Arak University of Medical 
Sciences. The study groups included 20 prostate 
cancer and 20 benign prostatic hyperplasia subjects. 
Sample size was calculated based on a pilot study 
(8). The inclusions and exclusion criteria for the PCa 
and BPH groups were as below:  
Inclusions criteria 
PCa group. Subjects with prostate cancer and 
without metastasis, chemotherapy and surgery, 
capable of giving informed consent, lack of specific 
diseases and no oral and dental disease. 
BPH group. Subjects without a history of 
prostate cancer that has been diagnosed by a 
specialist, capable of giving informed consent, lack 
of specific diseases and no oral and dental disease. 
 
Exclusion criteria 
PCa group. Subjects with benign tumors or 
already treated and having oral and dental disease. 
BPH group. Subjects with prostate cancer that 
has been diagnosed by a specialist and having oral and 
dental disease.  
The inclusions and exclusion criteria for this 
study was achieved by accurate laboratory analysis 
and under the supervision of consultant physician in 
urology medicine. The study was received ethical 
clearance and approval from Arak University of 
Medical Sciences,which was was consistent with the 
Helsinki Declaration. All of the subjects in the study 
were asked to completed a consent form of 
information questionnaire and demographic before 
sample collection. 
Blood and Saliva sample collection. Five 
milliliter of blood samples were taken from the 
participants by venipuncture, and centrifuged at 
3000rpm for 5 minutes. Unstimulated saliva was 
collected as follows: each participant were asked to 
and refrained from drinking, eating, and smoking or 
oral hygiene procedures for 2 hr before saliva 
collection. They rinsed her mouth with plain water 
several times and seat before collecting for ~15 min 
before collection. In general, each participant donated 
~5–10 ml of saliva. All saliva samples were 
centrifuged for 10 min at 3000 rpm to obtain clear 
supernatant. All sample were aliquot in tubes then 
coded for each test and was stored at -70°C for later 
determination of salivary and serum β2M. 
Analysis of salivary and serum β2M. Salivary 
and serum β2M levels were determined using 
sandwich enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer’s protocol. 
The kit was purchased from Bioassay technology 
laboratory (Shanghai, China), and is designed to 
quantify the β2M levels in biological fluids (serum, 
saliva, cell lysate etc.).The minimum β2M detection 
level reported by the manufacturer is 0.5 mg/dl. Intra-
and inter-assay coefficients of variation were <8 and 
<10%, respectively. All instruments were calibrated 
before use by second author. Sample absorbance at 
450 nm was measured with an ELISA reader (ELX 
800 TM ELISA reader Bio Tek, Winooski,VT, 
U.S.A).  
Statistical analysis. Mann Whitney U test (non-
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parametric test) were used for comparison between 
values of salivary and serum β2M in two groups. 
Correlations between salivary and serum β2M was 
assessed by applying Spearman’s correlation test. 
The p-value<0.05 was considered statistically 
significant. All Statistical analysis was done by 
software Graph Pad Prism software (Version 6.00). 
Results 
Demographic information. Demographic 
characteristics of the study groups are summarized in 
Table 1.The mean ± SEM age of PCa and BPH 
subjects were 50.95 ± 2.76 and 50.45 ± 2.61 years, 
respectively which  were  not significantly different 
between PCa and BPH groups (P=0.8).The body 
mass index for the PCa group was 22. 3 ± 0.6 and for 
the BPH group was 22.7 ± 0.5, that was no 
significant between two groups (P=0.7). All the 40 
participants were married. As well as, the two groups 
in terms of alcohol consumption and smoking were 
compared: Thirty-five percent of the PCa and twenty 
percent of the BPH cases were smoker but no subjects 
consumed alcohol.  
β2M levels in saliva and serum. The results 
showed that there was a significant difference between 
PCa and BPH in terms of β2M levels in saliva and 
serum (Table 2). The β2M level in serum of the PCa 
group (26.5±8.5) were higher than serum of the BPH 
group (7.0 ± 0.5), which was statistically significant 
(P=0.02). As well as, the β2M levels in saliva of the 
PCa group (11.4 ± 1.3) were higher than saliva of the 
BPH group (6.1 ± 0.5), that was statistically 
significant (P=0.0005). In general, it was found that 
the values of salivary β2M in all subjects were less 
than its serum. 
Correlation between salivary and serum β2M. 
There was a significant positive correlation  between 
salivary and serum β2M showed (Figure 1). In the PCa 
group (Figure1-A), saliva β2M level was correlated 
significantly and positive with serum β2M (r=0.747, 








Age ( Year) 50.95 ± 2.76 50.45 ± 2.61 0.8 
BMI (Kg/m2) 22. 3 ± 0.5 22.7 ± 0.5 0.7 
Tobacco usage 
35% 20%  
Alcohol usage 
0 0  
 
Data are expressed as mean ± SEM and P < 0.05 is statistically significant 
PCa: Prostate cancer; BPH: Benign prostatic hyperplasia; BMI: Body Mass Index 








β2M (Serum) mg/dl 8.5±26.5 0.5 mg/dl ±7.0 0.02 
β2M (Salivary) mg/dl 1.3±11.4 mg/dl 0.5±6.1 0.0005 
 
Data are expressed as mean (ng/ml) ± SEM and *P < 0.05 is statistically significant 
PCa: Prostate cancer; BPH: Benign prostatic hyperplasia; β2M: Beta-2 microglobulin 
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P<0.05). As well as, in the BPH group, salivary β2M 
levels were correlated significantly and positive with 
serum β2M (r=0.513, P<0.05; Figure1-B). 
Discussion 
There are many biological samples, but some 
of them are very important and acceptable for 
patients and clinical laboratory (11).On the other 
hand, since prostate diseases often occurs in adult 
men, the use of saliva due to its benefits as an 
inexpensive, non-invasive, simple, and  no painful 
method has been derived interest for diagnosis and 
monitoring  (12, 13) .Additionally, the  use of 
specific biomarkers owing to its advantages such as 
simple, low cost, relatively sensitive screening tool 
for monitoring prostate cancer and benign prostatic 
hyperplasia can be useful. Recently, interest in saliva 
as a biological sample for measure tumor markers 
has increased exponentially (14). For this purpose, in 
our study β2M were measured in saliva and serum to 
investigate its changes in prostate disease and the 
estimate the relationship between salivary and serum 
in this subjects. 
The results of our study showed that there was 
a significant difference between PCa and BPH in 
terms of serum and saliva β2M. These results suggest 
that the β2M can be effectively used for the diagnosis 
and differentiation of PCa and BPH. In addition, our 
results showed that there is a significant and positive 
correlation between salivary and serum β2M in both 
groups, as well as in all participants the salivary β2M 
was less than serum β2M. These results indicate the 
potential use of saliva to measure the β2M as an 
alternate to serum β2M in the future.  
 Studies have indicated that when β2M is 
released from the complex MHC-Ι acts as a ligand that 
bind to growth factors receptors and causes 
angiogenesis, growth and differentiation of the cells. 
The presence of β2M in biological fluids is due to lack 
of binding to the membrane, which increases at the 
time of cell turnover such as cancer and chronic 
infectious (15). In this regard, our results showed that 
level of β2M in serum of the PCa was significantly 
increased compared with BPH group. Consistent with 
this result, Gross et al. reported that the β2M 
significantly increased in prostate cancer patients 
compared to healthy subjects (16). Abdul et al. also 
showed that the value of β2M has been higher in urine 
of patients with androgen-independent prostate cancer 
compared to androgen-dependent prostate cancer (12). 
In addition Abdul et al. in another study, reported that 
the β2M on cells derived from patients with prostate 
cancer metastasis and in the urine of patients with 
bone and visceral metastases is higher than normal 
cells and healthy group, respectively (17), which these 
results are in agreement with our results. As well as, 
our data revealed that the β2M significantly increased 
in saliva of the PCa group compared to the BPH 
group. As well as, our findings indicted that serum of 
 
     
Figure 1. Correlation curves of salivary and serum β2M in PCa and BPH groups. The salivary β2M showed significantly and positive correlated 
with the serum β2M in two groups. This correlation coefficient was (r= 0.747, P<0.05: Figure 1-A) and (r=0.513, P<0.05: Figure 1-B) for PCa and 
BPH groups, respectively. Spearman's correlation coefficient (r) was used to analysis of the correlation between salivary and serum β2M.*P-value 
is for spearman correlation, P < 0.05 is statistically significant. 
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all participants had β2M higher than of their salivary 
and the significant positive correlation were observed 
between salivary and serum β2M in both groups. 
These results suggest that saliva as a non-invasive 
sample can reflect the serum value of  β2M. To our 
knowledge, this is the first study to evaluate saliva 
β2M in prostate patients and also determination of 
the correlation between salivary and serum β2M in 
these patients. However, Vahedi et al and Assareh et 
al in various studies showed that salivary β2M levels 
cannot be an indicator for diagnosis of patients with 
renal failure, but, in line with our results they 
reported the salivary levels of  β2M are less than the 
serum β2M (18, 19).  For further confirmation of our 
results in order to use saliva as a non-invasive 
samples, previous studies  showed that the 
correlation is positive and significant between the 
saliva and serum levels of other biomarkers in 
various diseases, such as cancer antigen (CA) 15-3 
and CA125 in breast cancer (20, 21), PSA in prostate 
cancer(8) and creatine phosphokinase (CPK) in 
patients with acute myocardial  infarction (22). In 
general, considering the  benefits of   tumor markers 
and also advantages of  saliva,  future studies are 
needed to investigate alterations of the other tumor 
markers in the prostate diseases and indicate whether 
the saliva can be used to evaluate tumor markers or 
not. 
Conclusion 
Our data underline the potential of β2M as a 
tumor marker for diagnosis and differentiation of 
prostate cancer and benign prostatic hyperplasia and 
confirm the possibility of using saliva as a possible 
diagnostic fluid. In conclusion, the positive and 
significant correlation between salivary and serum 
β2M found in our study suggests that saliva could be 
an alternative approach to blood for diagnosis and 
monitoring prostate diseases. However, further 
studies in other diseases, different parameters and a 
larger sample size are needed to confirm this 
decision. 
Conflicts of Interest 
The authors have no conflict of interest in this 
study. 
Acknowledgment 
The authors are grateful all the patients who 
took part in this study. This research was supported by 
a grant of deputy in research and technology, Arak 
Medical Science University, with ethic permission 
number IR.ARAKMU.REC.1394.2.  
References 
1. Nemer AMA, Aldamanhori RB. Prostatic diseases under focus in a 
university hospital in Eastern Saudi Arabia: A 15-year experience. 
Saudi Medical Journal. 2015;36(11):1319-23. 
2. Abdel-Meguid TA, Mosli HA, Al-Maghrabi JA. Prostate 
inflammation. Association with benign prostatic hyperplasia and 
prostate cancer. Saudi Med J. 2009;30(12):1563-7. 
3. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, 
Greene KL, et al. Early detection of prostate cancer: AUA Guideline. 
The Journal of urology. 2013;190(2):419-26. 
4. Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich 
B, et al. Differential blood-based diagnosis between benign prostatic 
hyperplasia and prostate cancer: miRNA as source for biomarkers 
independent of PSA level, Gleason score, or TNM status. Tumor 
Biology. 2016;37(8):10177-85. 
5. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, 
Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the 
staging of pelvic lymph nodes in patients with prostate cancer: a 
meta-analysis. Clin Radiol. 2008;63(4):387-95. 
6. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell 
A. Tumor markers in prostate cancer I: blood-based markers. Acta 
oncologica (Stockholm, Sweden). 2011;50(Suppl 1):61-75. 
7. Prizment AE, Linabery AM, Lutsey PL, Selvin E, Nelson HH, 
Folsom AR, et al. Circulating Beta-2 Microglobulin and Risk of 
Cancer: The Atherosclerosis Risk in Communities Study (ARIC). 
Cancer Epidemiol Biomarkers Prev. 2016;25(4):657-64. 
8. Shiiki N, Tokuyama S, Sato C, Kondo Y, Saruta J, Mori Y, et al. 
Association between saliva PSA and serum PSA in conditions with 
prostate adenocarcinoma. Biomarkers. 2011;16(6):498-503. 
9. Laidi F, Bouziane A, Lakhdar A, Khabouze S, Amrani M, Rhrab 
B, et al. Significant correlation between salivary and serum Ca 15-3 
in healthy women and breast cancer patients. Asian Pac J Cancer 
Prev. 2014;15(11):4659-62. 
10. Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays 
for detecting malignant ovarian tumors. Obstet Gynecol. 
1990;75(4):701-4. 
11. Liu J, Duan Y. Saliva: A potential media for disease diagnostics 
and monitoring. Oral oncology. 2012;48(7):569-77. 
12. Abdul M, Hoosein N, editors. Changes in beta-2 microglobulin 
expression in prostate cancer. Urologic Oncology: Seminars and 
Original Investigations; 2000: Elsevier. 
13. Segal A, Wong DT. Salivary diagnostics: enhancing disease 
detection and making medicine better. Eur J Dent Educ. 2008;1:22-9. 
14. Liu J, Duan Y. Saliva: a potential media for disease diagnostics 
and monitoring. Oral Oncol. 2012;48(7):569-77. 
15. Prizment AE, Linabery AM, Lutsey PL, Selvin E, Nelson HH, 
Folsom AR, et al. Circulating beta-2 microglobulin and risk of 
Amri et al.                             Significant relationship between Salivary and Serum β2-Microglobulin in Prostate Cancer …  
 Archives of Medical Laboratory Sciences 
134 
cancer: the Atherosclerosis Risk in Communities Study (ARIC). 
Cancer Epidemiology and Prevention Biomarkers. 2016:cebp. 
0849.2015. 
16. Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, et al. β-2-
microglobulin is an androgen-regulated secreted protein elevated in 
serum of patients with advanced prostate cancer. Clinical Cancer 
Research. 2007;13(7):1979-86. 
17. Abdul M, Banks M, Hoosein N. Urinary markers for prostate 
cancer. International journal of oncology. 1996;8(4):735-40. 
18. Assareh AA, Haybar H, Malekzadeh H, Yazdanpanah L, 
Bozorgmanesh M. No Relationship between Serum and Salivary 
β2-Microglobulin Levels in A Sample of Adult Diabetic Men with 
Chronic Kidney Disease without Renal Replacement Therapy. Cell 
Journal (Yakhteh). 2014;16(2):179. 
19. Vahedi M, Malekzadeh H, Haybar H, Soltanian AR, 
Abdollahzadeh S, Yoosefi H, et al. The relationship between salivary 
beta-2 microglobulin and uremia intensity in men with chronic renal 
failure. Cell Journal (Yakhteh). 2013;14(4):276. 
20. Laidi F, Bouziane A, Lakhdar A, Khabouze S, Amrani M, Rhrab 
B, et al. Significant correlation between salivary and serum Ca 15-3 
in healthy women and breast cancer patients. Asian Pac J Cancer 
Prev. 2014;15(11):4659-62. 
21. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A, Seilanian-Toosi 
M. Correlation of serum and salivary CA125 levels in patients with 
breast cancer. J Contemp Dent Pract. 2009;10(6):E001-8. 
22. Mirzaii‐Dizgah I, Jafari‐Sabet M. Unstimulated whole saliva 
creatine phosphokinase in acute myocardial infarction. Oral diseases. 
2011;17(6):597-600. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
